New Guardant Hereditary Cancer test offers germline testing to identify guideline-recommended genetic variants associated with cancer risk across 12+ tumor types
新Guardant遗传性癌症测试提供生殖系测试，以识别与12种以上肿瘤类型相关的指南推荐的遗传变异。
Results help guide treatment decisions and enable healthcare providers to assess patient risk for secondary cancers
结果有助于指导治疗决策，并使医疗保健提供者能够评估患者继发性癌症的风险。
PALO ALTO, Calif.--(BUSINESS WIRE)--
加利福尼亚州帕洛阿尔托--（商业资讯）--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Guardant Hereditary Cancer test, a germline test that identifies genetic variants associated with cancer risk to help cancer care teams provide optimal patient care.
Guardant Health, Inc.（纳斯达克股票代码：GH），一家领先的精准肿瘤学公司，今天宣布推出Guardant遗传性癌症测试，这是一种识别与癌症风险相关的基因变异的种系测试，旨在帮助癌症护理团队为患者提供最佳护理。
Germline genetic testing is recommended by medical practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention.
医学实践指南建议对癌症患者进行生殖系基因检测，以实现基因靶向治疗，并确定可能受益于个性化癌症筛查和预防的亲属。
1
1
The testing analyzes inherited genetic variants, typically present in all the cells of the body, that may predispose an individual to certain risks or diagnoses, including hereditary cancers and other genetic conditions. The new Guardant Hereditary Cancer test is a blood-based germline panel test that identifies guideline-recommended genetic variants across 82 genes associated with an increased risk for more than 12 tumor types, including breast, colorectal, prostate, endometrial, renal and others..
该测试分析了通常存在于身体所有细胞中的遗传变异，这些变异可能会使个体倾向于某些风险或诊断，包括遗传性癌症和其他遗传条件。新的Guardant遗传性癌症测试是一种基于血液的生殖系基因组测试，可识别与超过12种肿瘤类型（包括乳腺癌、结直肠癌、前列腺癌、子宫内膜癌、肾癌等）风险增加相关的82个基因中的指南推荐遗传变异。
“Introducing a best-in-class hereditary cancer test is another important step in achieving our mission to conquer cancer with data,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “It expands the portfolio we offer to support healthcare providers across the entire continuum of cancer care and allows them to access an even broader set of precision oncology tools through a single source.
“推出一流的遗传性癌症检测是我们实现用数据征服癌症使命的另一个重要步骤，”Guardant Health董事长兼联席首席执行官赫尔米·埃尔图克里表示。“它扩展了我们为支持医疗保健提供者在整个癌症护理过程中所提供的产品组合，并使他们能够通过单一来源获取更广泛的精准肿瘤学工具。”
The germline testing will help them develop more informed personalized treatment plans for patients, reduce risk and improve outcomes.”.
生殖细胞检测将帮助他们为患者制定更有根据的个性化治疗计划，降低风险并改善结果。"
Physicians may order the Guardant Hereditary Cancer test for patients with a personal or family history of hereditary cancer for several reasons, such as guiding treatment or care decisions, assessing risk for secondary cancer development, and providing information that can help identify other family members who may be at increased risk for certain cancers.
医生可能会为有遗传性癌症个人史或家族史的患者订购Guardant遗传性癌症检测，原因包括指导治疗或护理决策、评估继发癌症发展的风险，并提供信息帮助识别其他可能面临某些癌症风险增加的家庭成员。
Discussion of risk-reducing strategies, enhanced screening, and referral to a specialist or genetic counseling is recommended..
建议讨论降低风险的策略、加强筛查，并转诊给专科医生或遗传咨询。
The Guardant Hereditary Cancer test requires only a simple blood draw and can be ordered as a standalone test or added to Guardant360 liquid biopsy tests with no additional sample required. Results are available in two to three weeks.
Guardant Hereditary Cancer测试只需简单的抽血，可以作为独立测试订购，或加入到Guardant360液体活检测试中，且无需额外样本。结果在两到三周内即可获得。
About Guardant Health
关于Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics.
Guardant Health 是一家领先的精准肿瘤学公司，专注于守护健康，让每个人拥有更多免受癌症困扰的时间。自 2012 年成立以来，Guardant 通过其先进的血液和组织检测、真实世界数据以及人工智能分析，提供对疾病驱动因素的关键洞察，从而改变患者护理并加速新的癌症治疗方法的发展。
Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on .
Guardant测试有助于改善各个护理阶段的效果，包括早期癌症筛查、早期癌症复发监测以及晚期癌症患者的治疗选择。欲了解更多信息，请访问guardanthealth.com并关注该公司。
领英
,
，
X (Twitter)
X（推特）
and
和
.
。
Forward-Looking Statements
前瞻性声明
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements.
本新闻稿包含联邦证券法意义上的前瞻性声明，包括关于 Guardant Health 液体活检测试或检测方法的潜在效用、价值、益处和优势的声明，这些声明涉及风险和不确定性，可能导致实际结果与此类前瞻性声明中表达的预期结果和期望存在重大差异。
These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter.
这些声明基于当前的预期、预测和假设，由于许多因素，实际结果可能与这些声明有重大差异。这些以及可能影响Guardant Health财务和运营结果并导致实际结果与本新闻稿中所做的前瞻性声明所表明的结果有重大差异的额外风险和不确定性，包括在其截至2024年12月31日的年度Form 10-K报告中“风险因素”和“管理层对财务状况及经营结果的讨论与分析”标题下及其他部分讨论的内容，以及其后向证券交易委员会提交或递交的其他报告中所涉及的内容。
The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.
本新闻稿中的前瞻性陈述基于Guardant Health截至本日期可获得的信息，Guardant Health拒绝承担更新任何前瞻性陈述的义务，以反映其预期的任何变化或任何相关事件、条件或情况的变化，除非法律要求。
These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release..
这些前瞻性陈述不应被视为代表Guardant Health在本新闻稿发布日期之后的任何日期的观点。
References
参考文献
1.
1.
JAMA.
美国医学会杂志。
2023;330(1):43-51. doi:10.1001/jama.2023.9526.
2023;330(1):43-51. doi:10.1001/jama.2023.9526.
Investor Contact:
投资者联系方式：
Zarak Khurshid
扎拉克·胡尔希德
investors@guardanthealth.com
投资者@gardanthealth.com
Media Contact:
媒体联系人：
Michael Weist
迈克尔·魏斯特
press@guardanthealth.com
press@guardanthealth.com
+1 317-371-0035
+1 317-371-0035
Source: Guardant Health, Inc.
来源：Guardant Health, Inc.
精彩评论